- Company
- Medytox submits BLA to FDA for its next-gen botulinum
- by Chon, Seung-Hyun Dec 29, 2023 05:39am
- Medytox is working to enter the U.S. market with its next-generation botulinum toxin product, which technology has been reverted to the company after being transferred to a foreign company. On the 27th, Medytox announced that it has filed a biological license application (BLA) to the U.S. Food and Drug Administration (FDA) for its next-gen
- Company
- Hugel Resolves to Retire 371,563 shares of its own stock
- by Nho, Byung Chul Dec 28, 2023 01:14pm
- Hugel, a global total medical aesthetics company, announced that it has held a board of directors meeting on the 22nd and passed a resolution to retire 371,563 shares of its own stock to enhance the shareholder’ value. This is equivalent to around 3% of the total outstanding shares (12,385,455 shares), and the expected value of the retired s
- Company
- Tezspire lands in Korea…joins 6-way race
- by Dec 28, 2023 06:02am
- The new drug for severe asthma that emerged joined the competition with the five existing biologics that were being used in Korea. AstraZeneca, which recently received domestic approval for its new drug, plans to differentiate itself from existing treatment options with new mechanisms of action and formulations. According to industry sources
- Company
- Acetaminophen syrup receives price hikes to meet demand
- by Chon, Seung-Hyun Dec 28, 2023 06:02am
- Starting next month, the maximum reimbursement prices for two acetaminophen suspension formulations will be increased by over 50%. The price hike follows the government’s decision to implement measures aimed at encouraging pharmaceutical companies to expand volume of acetaminophen production. Currently, there is a continuous demand for the drug
- Company
- Genexine completes trial on its long-acting anemia drug
- by Son, Hyung-Min Dec 28, 2023 06:02am
- Genexine’s new drug candidate for chronic kidney disease-induced anemia, Efesa, has confirmed its efficacy through clinical trials. Genexine plans to confirm the drug’s competitiveness in the oversaturated anemia treatment market with its long-acting formulation. According to the Financial Supervisory Service, Genexin recently announced tha
- Company
- KRW 250 bil market shakes from reimb reevaluations
- by Chon, Seung-Hyun Dec 28, 2023 06:02am
- The pharmaceutical industry has expressed great disappointment regarding the results of the government’s drug reimbursement reevaluations. The reimbursement scope of three ingredients - loxoprofen, limaprost alpha dex, and epinastine hydrochloride - will be reduced. This is a loss worth KRW 250 billion in the prescription market. The losses
- Company
- Generic companies win 3 out 4 patent disputes
- by Kim, Jin-Gu Dec 27, 2023 11:39am
- This year, out of 29 trial decision and verdict cases that arose as patent disputes, companies that filed a trial or lawsuit have won in 21 cases. This translates to a win rate of approximately 76% for companies challenging patents. Especially, excluding cases where the lawsuit or suit qualification was deemed ineligible, the dispute hadn’t
- Company
- Keytruda's indication expanded for early-stage lung cancer
- by Son, Hyung-Min Dec 27, 2023 06:05am
- MSD’s immuno-oncology drug Keytruda has been approved for early-stage lung cancer, totaling its indication count to 25. With the latest approval, Keytruda became the third treatment, alongside AstraZeneca’s Tagrisso and Roche’s Alecensa, that can be used as neoadjuvant and adjuvant therapy. With major lung cancer treatment now approved for ea
- Company
- LegoChem licenses out ADC technology... a KRW 2.2 tril deal
- by Son, Hyung-Min Dec 27, 2023 06:03am
- LegoChem Biosciences' TROP2 targeted antibody-drug conjugate technology has been licensed out to Janssen. By signing a total of 13 technology transfer and option agreements in the field of ADC alone this year. According to industry sources, LegoChem Biosciences signed a technology transfer agreement with Janssen on the 26th for its TROP2 targ
- Company
- Reimbursed Leclaza nears annual sales of 1T won
- by Chon, Seung-Hyun Dec 26, 2023 01:11pm
- Yuhan Corp.'s new cancer drug, Leclaza, swiftly wins reimbursement listing for its use as a first-line treatment. Following success with its second-line treatment, Leclaza received reimbursement for the first-line treatment within just six months of approval. The second-line treatment alone has generated quarterly sales of 6 billion won and
